Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71335-0509

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-0509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of the active ingredient in Duloxetine Delayed-Release 60 mg, showing its molecular arrangement including aromatic rings, heteroatoms, and functional groups associated with duloxetine hydrochloride.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time in days after randomization. It compares two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line), with the y-axis representing the proportion of patients with relapse and the x-axis representing days from randomization to relapse.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line chart comparing the proportion of patients with relapse over time (days) between placebo and Duloxetine delayed-release capsules. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. The placebo group shows a higher and faster increase in relapse proportion compared to the Duloxetine delayed-release capsules group.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four groups are compared: DULOXETINE DELAYED-RELEASE 60 mg twice daily (BID), 60 mg once daily (QD), 20 mg once daily (QD), and placebo. The graph shows the trend of patient improvement across increasing thresholds of pain improvement.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: DULOXETINE DELAYED-RELEASE 60 mg BID, DULOXETINE DELAYED-RELEASE 60 mg QD, and placebo. The vertical axis represents the percentage of patients improved, and the horizontal axis represents the percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: DUL 60mg twice daily, DUL 60mg once daily, and placebo, illustrating their relative effectiveness in pain improvement over a range from 0 to 100%.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four curves represent groups receiving DULOXETINE DELAYED-RELEASE at doses of 20 mg, 60 mg, and 120 mg once daily, and a placebo group. The y-axis shows percentage of patients improved from 0% to 100%, and the x-axis shows percent improvement in pain from baseline with interval markings.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups, placebo and DULOXETINE DELAYED-RELEASE (60/120 mg once daily), using plotted points connected by lines over increasing pain improvement percentages from greater than 0 to 100%.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved by the percent improvement in pain from baseline, contrasting placebo with DULOXETINE DELAYED-RELEASE 60 mg once daily. The X-axis shows percent improvement in pain from baseline (BOCF) from >0 to 100, and the Y-axis shows the percentage of patients improved from 0 to 100%. The graph features two plotted lines, one for placebo and one for DULOXETINE 60 mg once daily, indicating higher percentages of patient improvement for DULOXETINE across the range.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and DULOXETINE DELAYED-RELEASE 60/120 mg once daily. The graph shows two curves with the DULOXETINE line generally higher, indicating a higher percentage of patients improved at various pain improvement thresholds.*

FDA Label Image

Label (Lbl713350509)

Duloxetine Delayed-Release 60 mg Capsule packaging label from Bryant Ranch Prepack. The label compares to Cymbalta 60 mg Capsule, includes storage instructions (20-25°C), a warning about potential drowsiness, and a caution to keep out of children's reach. The NDC is 71335-0509, with a pack size of 30 capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.